IRVINE, Calif., Nov. 8, 2019 /PRNewswire/ -- AIVITA Biomedical,
Inc., a biotech company specializing in innovative stem cell
applications, today announced that new data from its ongoing Phase
2 clinical trial in glioblastoma multiforme will be presented at
the Society for Immunotherapy of Cancer Annual Meeting by Lead
Principal Investigator Dr. Daniela
Bota. The podium presentation will detail early encouraging
survival data, immune response data and tumor biomarker and imaging
data. Details for the oral presentation are as follows:
Meeting: Society for Immunotherapy of Cancer Annual
Meeting
Presenter: Dr. Daniela Bota, MD, PhD, University of California, Irvine; AIVITA GBM Lead
Principal Investigator
Title: Phase II trial of therapeutic vaccine consisting of
autologous dendritic cells loaded with autologous tumor cell
antigens from self-renewing cancer cells in patients with newly
diagnosed glioblastoma
Session: Session 311: A Tale of Two Brain Tumors: Primary
versus Metastatic CNS Tumors
When: 6:15 PM ET, Saturday Nov 9
Location: Gaylord National Hotel & Convention Center,
National Harbor, MD
About AIVITA Biomedical
AIVITA Biomedical is a privately held company engaged in the
advancement of commercial and clinical-stage programs utilizing
curative and regenerative medicines. Founded in 2016 by pioneers in
the stem cell industry, AIVITA Biomedical utilizes its expertise in
stem cell growth and directed, high-purity differentiation to
enable safe, efficient and economical manufacturing systems which
support its therapeutic pipeline and commercial line of skin care
products. All proceeds from the sale of AIVITA's skin care products
support the treatment of women with ovarian cancer.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/brain-cancer-patient-survival-immune-and-tumor-data-from-aivita-biomedicals-phase-2-clinical-trial-to-be-presented-at-sitc-annual-meeting-300954923.html
SOURCE AIVITA Biomedical, Inc.